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Creutzfeldt-Jakob disease (CJD) is a human prion disease occurring with sporadic, genetic, or infectious etiologies. The agents responsible for these diseases are prions, which are altered forms of the ubiquitously and normally expressed prion protein (PrP). The most common form of prion disease in humans is sporadic CJD (sCJD), characterized by a spectrum of variable clinical signs evolving over a period of weeks to months. Early and accurate diagnosis has been a long standing difficulty, currently relying heavily on combinations of clinical features, specifically MRI and EEG changes, and the detection of surrogate markers such as the 14-3-3 protein in CSF. 1 Such criteria can yield diagnoses of probable or possible sCJD, however, according to current international ª 2016. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
guidelines, definite diagnosis requires the detection of pathological prion protein (PrP CJD ) in the central nervous system tissue. Because the acquisition of such tissue requires brain biopsies 2 or autopsies, most definitive diagnoses are made postmortem.
The Real-Time Quaking-Induced Conversion (RTQuIC) and the amyloid seeding (ASA) assays exploit the ability of PrP CJD to seed the polymerization of protease sensitive recombinant PrP (rPrP sen ) into amyloid fibrils detectable by thioflavin-T (ThT) fluorescence. [3] [4] [5] This test allows for rapid, sensitive, and quantitative detection of prion-associated seeds in a variety of biological tissues and fluids. [6] [7] [8] [9] [10] [11] [12] [13] [14] Recently the RT-QuIC has been used for sensitive and specific detection of PrP CJD in human cerebrospinal fluid 5, [15] [16] [17] [18] [19] which is much easier than brain tissue to obtain from live patients. Numerous laboratories have implemented and extensively assessed the use of RT-QuIC analysis of CSF for intra vitam diagnosis of CJD using hamster or human rPrP sen with amino acids 23-231 as the substrate, no detergents, and 37 or 42°C incubations. [13] [14] [15] [16] [17] [18] These assays require 2.5-5 days and miss 11-23% of CJD cases. We call our version of this generation of the assay PQ-CSF, for previous RT-QuIC for CSF. 19 However, we recently described an improved, second generation RTQuIC for CSF (IQ-CSF) assay which uses a truncated form of hamster rPrP Sen (amino acids 90-231) as a substrate, 55°C incubations, and the addition of 0.002% sodium dodecyl sulfate (SDS). Our initial evaluation of the IQ-CSF assay indicated enhanced fluorescence responses to sCJD seeds, greater analytical and diagnostic sensitivity, and markedly shorter testing times of~4-24 h. 19 For this study, we analyzed a new and larger panel of CJD patients and, for the first time, directly compared the performance of the PQ-and IQ-CSF conditions when tested simultaneously on the same specimens. CSF samples were gathered at multiple locations in Italy including the University of Verona (Verona), Ospedale Maria Vittoria (Torino), and Istituto Superiore di Sanit a (Rome). All of the 177 CSF samples, 113 CJD, and 64 non-prion disease patients were tested blindly. Final diagnosis of the prion disease patients revealed 36 definite, 68 probable, three genetic CJD (including one E200K, and two V210I) cases, and one P102L Gerstmann-Straussler-Scheinker (GSS) syndrome case. Table S1 shows the demographic and clinical information for each prion disease patient, as well as 14-3-3 and tau measures when available. Direct comparative analysis of each sample using PQ-and IQ-CSF RT-QuIC conditions was done within the same experiment, using the same solutions and materials. Non-prion disease control patients included 21 males and 43 females with an average age of 65 AE 18 years (mean AE SD). Eighteen patients had diagnoses of non-neurological disease and 46 patients had non-prion neurological diseases including: amyotrophic lateral sclerosis (n = 3), Alzheimer's disease (n = 3), chronic inflammatory demyelinating polyneuropathy (n = 1), cognitive decline (n = 13), dystonia (n = 1), frontotemporal dementia (n = 9), lewy body dementia (n = 1), mild cognitive impairment (n = 4), multiple system atrophy (n = 1), Parkinsonism (n = 1), and rapidly progressive dementia (n = 9). Figure 1A shows the comparison of the average RTQuIC amplification kinetics for CJD and non-prion disease CSF using PQ-or IQ-CSF assays. Using PQ-CSF and our previously established criteria for signal thresholds and time cutoffs 6, 19 , a majority of samples scored positive after 47 h and full analysis typically required at least 90 h ( Fig. 1A and B) . ThT fluorescence amplitudes averaged 26% of our maximum reading capacity with only 16% of the samples registering above 50% (Fig. 1C ). The same samples tested on the same day by IQ-CSF RT-QuIC showed significantly stronger fluorescence readings ( Fig. 1A and Table 1 ) and faster amplification kinetics (Fig 1B, P < 0.0001, Mann-Whitney test) with the majority of positives being detected within 10 h and assay concluded within 24 h ( Fig. 1A and B) . IQ-CSF conditions averaged 85% of our maximum reading capacity with 84% of the readings being greater than 50% and 68% of all samples reading 100% ( Fig. 1A and C) . The median percent maximum ThT readings for PQ and IQ-CSF conditions were 22 and 100%, respectively.
We calculated our ThT fluorescence threshold for a reaction to be considered positive based on the mean ThT value of all negative control samples at 90 h for PQ-CSF, or 24 h for IQ-CSF, plus 10 standard deviations 6, 19, 20 . This generated thresholds of~2 and~6% of saturating fluorescence for PQ-CSF and IQ-CSF, respectively. In addition, as has been common in previous studies 6, 19 , because of the rare occurrence of single wells exceeding the threshold in non-prion disease controls within the cutoff time of the reaction, at least two of four replicate reactions had to each exceed the threshold for a sample to be considered overall positive. Since these cutoffs are based on the signal to noise ratio of the negative control samples, careful consideration was given to the designated cutoff value in order to maximize sensitivity without compromising specificity. Although the specificity for both protocols was 100% (CI: 93-100%), under PQ-CSF conditions only 82 out of the 113 CJD samples tested positive (Table 1) , leading to a 73% (95% CI: 63-80%) sensitivity. The same sample set analyzed by IQ-CSF resulted in 106 positive specimens out of 113 tested, giving a 94% (CI: 87-97%) sensitivity. Sensitivities by IQ-CSF for probable and definite CJD diagnoses were 97% and 92%, respectively. Furthermore, MM, MV, and VV polymorphisms at codon 129 had sensitivities by IQ-CSF of 98, 96, and 90%, respectively. None of the non-prion disease patients' samples showed fluorescence that exceeded the designated threshold. Maximum ThT fluorescence values for non-prion disease patients were under 0.9% and 3.0% of saturation for PQ-and IQ-CSF, respectively. PQ-CSF conditions produced an average maximum ThT fluorescence of 0.4 AE 0.2% (mean AE SD) with a median of 0.4% while IQ-CSF conditions produced an average of 1.2 AE 0.5% (mean AE SD) with a median of 1.0%.
A comparison (Fig. 1B) of the time to threshold (hours) of the 82 positive PQ-CSF versus the 106 positive IQ-CSF samples further illustrates how much faster IQ-CSF kinetics are compared to PQ-CSF. Figure 1C shows the peak fluorescence values from the average of four replicate wells for each sample for PQ-and IQ-CSF tests ( Fig. 1C and Table 1 ). The baselines were subtracted from the data of the averaged individual samples and normalized to the saturating ThT fluorescence level of the plate reader (as described previously 6, 19 ). These results illustrate that IQ-CSF allowed significantly stronger discrimination between CJD-positive and non-prion disease control CSF samples. Although IQ-CSF did not detect seeding activity in all of the 113 CJD patients (Table 1 , see patients 1, 34, 92, 98, and 106-108), it was positive for all of those who were positive by PQ-CSF as well as 24 additional patients who were negative by PQ-CSF (Table 1 , blue shading). When the sample codes were broken, we discovered that duplicate aliquots from five patients had been tested within the panels as replication controls. The duplicate aliquots from the same patients were consistently positive with IQ-CSF but were not as consistent in the PQ-CSF analyses (Table 1, . Additionally, all of the seven CJD patients who were negative by IQ-CSF were also negative by PQ-CSF (Table 1 , yellow shading), suggesting that prion seeding activity in these samples was below the detection limit of both assays.
Overall, this faster and more sensitive IQ-CSF assay provided a~21% increase in diagnostic sensitivity and ã 42-h reduction in average detection time for positive samples, while maintaining 100% diagnostic specificity. A much larger sample size tested across multiple laboratories will be required to fully validate these new IQ-CSF These values indicate the normalized ThT response (described in 6, 19 ) for each patient at the determined cutoff time (90 h end point for PQ-CSF and peak value within 24 h for IQ-CSF conditions). Samples scored positive (orange) when the response was above the calculated threshold. Samples that were negative under only one condition are marked in blue, while sample that were negative under both conditions are marked in yellow. None of the non-prion disease patients' samples crossed threshold with ThT fluorescence values ranging from 0 to 0.9 or 3.0 for PQ-and IQ-CSF, respectively. The following sub-set of CJD samples have been previously analyzed: one CJD patient tested by IQ-CSF, seven by PQ-CSF, and two by both PQ-and IQ-CSF 21 ; Sixteen non-prion disease patients were previously tested either by PQ-CSF 6 or 18 were tested by IQ-CSF. 19 Here we reassayed all of these samples using both PQ-and IQ-CSF within the same experimental setup. 1 Only one of four wells crossed threshold and is therefore not considered a positive.
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Published 2016. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association conditions; however, our direct comparison confirms that IQ-CSF allows for considerably faster and more sensitive detection of PrP CJD seeding activity in CSF samples from CJD patients. Therefore, with many diagnostic laboratories around the world already implementing PQ-like RT-QuIC analysis of CSF, we expect that the diagnostic criteria for sCJD will soon be revised to include direct detection of PrP CJD in CSF, or olfactory mucosal samples 6 , by assays such as RT-QuIC. In clinical practice, IQ-CSF testing, more so than PQ-CSF testing, should have the ability to confirm CJD diagnoses or rapidly divert diagnoses to potentially treatable conditions, providing better outcomes for patients.
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